|
||
| |||||||
|
Morphochem provides novel lead compounds for further development from successful collaboration
Munich, Germany, 20th May 2005…Morphochem
AG, a leader in the evolutionary discovery of small molecule drugs today
announced the successful completion of their first research agreement with
Novartis, with the licensing of certain compounds discovered by Morphochem for
further development at Novartis.
Under the terms of the agreement, Morphochem has applied the MOREsystem®, its proprietary design, synthesis and screening technology, to identify novel small molecules outside of existing Intellectual Property, against three non disclosed targets provided by Novartis.
For the duration of the agreement, Morphochem received research funding and is
eligible for future milestone payments on the licensed compounds. “We are very
pleased that we could demonstrate the speed and efficiency of Morphochem’s
discovery engine to identify novel, “drug-able” molecules outside existing
intellectual property, so as to provide Novartis with alternative options for
their development programs” Sijmen de Vries, MD, MBA, Chief Executive Officer
of Morphochem, stated.
-ends- Notes
Morphochem AG (www.morphochem.com) a
privately owned company based in Munich and Basel has developed a unique and
highly integrated fast chemical genomics Drug Discovery Engine that it is
applying in several 3th party research programs and for building its own fully
owned pipeline. The current lead products in this pipeline; MCM 17 a novel
oral anti-thrombotic (Factor Xa inhibitor) and MCB3837 a unique Oxaquin® Dual
Action IV Hospital Antibiotic are planned to enter Clinical Trials towards the
end of 2005. In addition, as the fast Discovery Engine enables “Fast Follower”
development projects on “hot targets”, in addition, the Morphochem pipeline
also contains a number of original lead- stage projects against various proven
targets.
Morphochem:
Dr Sijmen de Vries, CEO Tel: +49 (0)89 78 00 50 sijmen.devries@morphochem.de Dr Peter Seufer Wasserthal Tel: +43 (0)7673 321 511 peter.seufer@morphochem.de Media relations: Northbank Communications Sue Charles
Tel: +44 (0) 20 7886 8152
s.charles@northbankcommunications.com Dr Eileen Paul Tel: +44 (0)1260 296516 e.paul@northbankcommunications.com
|
|
| ||||||||